| ENTITY |
POTENCY |
SAFETY INFORMATION |
EVIDENCE |
PMID |
| ?Ef11/?FL1C(?36)PnisA | The results showed a 10-100-fold decrease in viable cells (CFU/biofilm) after phage treatment, which was consistent with comparisons of treated and untreated biofilm images visualized as max projections of the Z-series. | | A potential alternative to antibiotic therapy is phage therapy. ?Ef11 is a temperate phage that infects strains of E. faecalis. | 27448990 |
| phiEF24C | phiEF24C phage had a shorter latent period and a larger burst size than ordinary tailed phages, indicating that phiEF24C has effective lytic activity against many Enterococcus faecalis strains, including VRE. | | Bacteriophage (phage) therapy is frequently proposed as a potential alternative therapy for infections caused by this bacterium. | 18096017 |
| bacteriophage isolated by enrichment from hospital sewage sludge. | Bacteriophage specific for A. baumannii to resolve wound infection in uncontrolled diabetic rats was evaluated. | | Bacteriophage therapy is a possible alternative treatment for multidrug-resistant (MDR) bacterial infections. | 25411824 |
| phage ZZ1 | ZZ1 is highly infectious with a short latent period (9 min) against A. baumanni clinical isolates AB09V, AB0902, and AB0901.. | | Bacteriophage therapy is a potential alternative treatment for multidrug-resistant bacterial infections. | 22838726 |
| Phage ?km18p | Combination of phages (?km18p, ?TZ1 and ?314) as a cocktail could lyse all genotype-varying XDRAB isolates. | | CONCLUSION: Infections with XDRAB are extremely difficult to treat and development of a phage cocktails therapy could be a therapeutic alternative in the future. | 23071586 |
| bacteriophage-therapy (phage) alone or combined with antibiotics | In vitro, single-dose phage therapy killed 7 log colony-forming units (CFUs)/g of fibrin clots in 6 hours.: In vivo, single-dose phage therapy killed 2.5 log CFUs/g of vegetations in 6 hours (P < .001 vs untreated controls) and was comparable with ciprofloxacin monotherapy. | | Conclusions: Single-dose phage therapy was active against P. aeruginosa EE and highly synergistic with ciprofloxacin. | 28007922 |
| bacteriophage TPR7 as antibacterial | Bacteriophages can effectively remove clinically resistant E. coli strains | | Currently, with the rapid spread of multi-drug resistant bacteria, phage therapy can be an effective alternative treatment for antibiotic resistant bacteria. | 25834712 |
| lytic phage EcSw | Inhibition of E. coli Sw1 and 0157:H7 strains | | Functional characterization of a novel lytic phage EcSw isolated from Sus scrofa domesticus and its potential for phage therapy. | 25805216 |
| encapsulation of bacteriophage ?eyfp and the mycobacteriophage TM4 into giant liposomes | | | Here we report effective encapsulation of the model bacteriophage ?eyfp and the mycobacteriophage TM4 into giant liposomes. Furthermore, we show that liposome-associated bacteriophages are taken up into eukaryotic cells more efficiently than free bacteriophages. | 25937143 |
| lysin CF-301 | CF-301 reduced S. aureus by 3-log10 within 30 minutes compared to 6-12 hours required by antibiotics | | Lysin CF-301 is being developed to treat Staphylococcus aureus because of its potent, specific, and rapid bacteriolytic effects. | 24286983 |
| phages KS12 and KS14 | B. cenocepacia K56-2-infected Galleria mellonella larvae treated with phage KS12 and low-dose meropenem demonstrated increased survival over controls treated with KS12 or antibiotic alone. | | One proposed alternative treatment is phage therapy, the therapeutic application of bacterial viruses (or bacteriophages). These results suggest that antibiotics can be combined with phages to stimulate increased phage production and/or activity and thus improve the efficacy of bacterial killing. | 25452284 |
| bacteriophage lysin CHAP(K) | | | Our findings demonstrate the potential for development of CHAP(K) as an alternative therapeutic against pathogenic staphylococci including MRSA. | 21812876 |
| Phage lytic enzyme Cpl-1 | | | Recombinant Cpl-1, a phage lysin specific for S. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. | 18471063 |
| Combinations of T4 bacteriophage and cefotaxime | The addition of medium (10(4) PFU mL(-1)) and high (10(7) PFU mL(-1)) phage titres reduced the minimum biofilm eradication concentration value of cefotaxime against E. coli ATCC 11303 biofilms from 256 to 128 and 32 ?g mL(-1), respectively. | | Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. The potential application of phage therapy for the control of bacterial biofilms has received increasing attention as resistance to conventional antibiotic agents continues to increase. | 22524448 |
| Phage Therapy: T4-like phage Bp7 | For larger yields, its optimal multiplicity of infection (MOI) to infect E. coli was about 0.001. The latent period was 10 to 15 min, and the burst size was 90 PFU/infected cell. It was stable both at pH 5.0 to 10.0 and at 40?C or 50?C for at least 1 h. Bp7 could infect 46% of pathogenic clinical E. coli strains. | | T4-like phage Bp7, a potential antimicrobial agent for controlling drug-resistant Escherichia coli in chickens. Chicken-pathogenic Escherichia coli is severely endangering the poultry industry in China and worldwide, and antibiotic therapy is facing an increasing problem of antibiotic resistance. | 23835183 |
| Broad-spectrum bacteriophage cocktail | The ratio of 10 bacteriophage particles per bacterial cell (MOI=10(1)) was efficient in inhibiting at least 50% of all isolates. | | The use of pathogenic-specific antimicrobials, as proposed by bacteriophage therapy, is expected to reduce the incidence of resistance development. | 20059909 |
| HydH5, a virion-associated muralytic enzyme of S. aureus bacteriophage vB_SauS-phiIPLA88 (phiIPLA88) | high antibiotic activity against early exponential cells, at 45?C and in the absence of divalent cations (Ca2+, Mg2+, Mn2+) | | The virion-associated PG hydrolase HydH5 has lytic activity against S. aureus, which makes it attractive as antimicrobial for food biopreservation and anti-staphylococcal therapy. | 21682850 |
| bacteriophage lysin, designated LySMP | biofilm removal with >80% greater efficacy | | These data suggest that bacteriophage lysin could form part of an effective strategy to treat S. suis infections and represents a new class of antibiofilm agents. | 21984241 |
| phi MR11 | In contrast, subsequent intraperitoneal administration of purified phi MR11 (MOI > or = 0.1) suppressed S. aureus-induced lethality. | Inoculation with high-dose phi MR11 alone produced no adverse effects attributable to the phage. | These results uphold the efficacy of phage therapy against pernicious S. aureus infections in humans and suggest that phi MR11 may be a potential prototype for gene-modified, advanced therapeutic S. aureus phages. | 12599078 |
| Cpl-1 | A 2000- microg dose of Cpl-1 reduced pneumococcal titers from a median of log(10) 4.70 CFU/ml to undetectable levels ( | | We report the use of Cpl-1, the lytic enzyme of a pneumococcal bacteriophage, as an intravenous therapy for pneumococcal bacteremia in a mouse model. | 14573637 |
| Salmonella-specific bacteriophages UAB_Phi20, UAB_Phi78, and UAB_Phi87 | | | Widespread antibiotic resistance has adversely affected human health and has encouraged the search for alternative antimicrobial agents. The advances in bacteriophage therapy highlight their use in controlling a broad spectrum of food-borne pathogens. | 27148229 |
